Skip to content
A Blog by Biocon

A Blog by Biocon

  • Home
  • About Us
  • Healthcare
  • Innovation
  • Vodcast
  • Bioconites Corner
    • Work From Home
    • Campaigns
      • Har Ghar Tiranga
      • Mother’s Day
      • Lupus Day
  • Policy
  • Comments Policy
  • Contact

Tag: #biosimilar #trastuzumab #o

December 5, 2017December 5, 2017 Biocon Biosimilar, Innovation

Biocon’s Landmark Achievement of First USFDA approval for Biosimilar Trastuzumab applauded by all including the Media

First Biosimilar Trastuzumab approved in the US

Watch How Biocon Biosimilars Are Expanding Access to Cancer Care

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg

Follow Biocon

Search

Biocon Limited

20th KM, Hosur Road,
Electronic City,
Bangalore, India - 560 100
Email: contact.us@biocon.com
+91 80 2808 2808 / 91 80 4014 4014

Archives

DISCLAIMER

Please read our Disclaimer and Comments Policy before engaging on our blog!

Create a website or blog at WordPress.com
Loading Comments...